

Special Issue

Novel Therapies for Neurodegenerative Disorders

Message from the Guest Editors

Neurodegenerative diseases, a collective term for progressive conditions affecting neurons and other supporting cells in the brain, manifest as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD) and stroke. AD and related dementia is a major concern faced by the elderly population. AD is the most common type of dementia, accounting for 60–70% of dementia cases. The underlying pathological mechanism is complex, eluding the successful development of a drug therapy. Therapies aimed at controlling amyloid beta and tau phosphorylation have resulted in limited success. With the rise in neurodegenerative diseases, it has become apparent that novel therapeutic targets should be pursued, as conventional ones yield limited results. This Special Issue aims to present recent findings within the broad field of neurodegenerative disease research on drug discovery to provide new mechanistic insights that could help researchers broaden the horizon of neurodegenerative disease drug discovery and development. Authors are invited to submit relevant original research articles, as well as opinion and review papers.

Guest Editors

Dr. Zahoor Shah

Department of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, The University of Toledo, Toledo, OH 43614, USA

Dr. Faheem Shehjar

Department of Medicinal and Biological Chemistry, University of Toledo, Toledo, OH 43614, USA

Deadline for manuscript submissions

closed (28 February 2025)



Journal of Dementia and Alzheimer's Disease

an Open Access Journal
by MDPI



mdpi.com/si/195595

Journal of Dementia and Alzheimer's Disease
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jdad@mdpi.com

mdpi.com/journal/

[jdad](https://jdad.mdpi.com)





Journal of Dementia and Alzheimer's Disease

an Open Access Journal
by MDPI



[mdpi.com/journal/
j dad](https://mdpi.com/journal/jdad)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Magda Tsolaki

1. Chair of Greek Federation of Alzheimer's Disease, 54643
Thessaloniki, Greece

2. 1st Department of Neurology, Aristotle University of Thessaloniki,
54124 Thessaloniki, Greece

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

first decisions in 19 days; acceptance to publication in 4 days (median values for MDPI journals in the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.